Trial reportInternational wound journal2023
Perilesional injections of human platelet lysate versus platelet poor plasma for the treatment of diabetic foot ulcers: A double-blinded prospective clinical trial.
Trial report in International wound journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Systematic review of the efficacy and safety of biologically and tissue-derived therapies for the treatment of diabetic foot.Frontiers in endocrinology · 2026Pooled it
- Human umbilical cord mesenchymal stromal cells derivatives in treating diabetic foot ulcers: a phase I/II safety and efficacy trial.Stem cell research & therapy · 2025Trial
- Perilesional injections of human platelet lysate versus platelet poor plasma for the treatment of diabetic foot ulcers: A double-blinded prospective clinical trial.International wound journal · 2023Trial
- Expired apheresis platelet-derived exosomes promote cutaneous wound healing.Scientific reports · 2026Article
- Self-regulating hydrogel for diabetic wound healing: From animal models to a pilot clinical study.Science advances · 2026Article
- Article
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Blood derivatives as monotherapy and combination therapy: A promising strategy for wound healing.Regenerative therapy · 2025Review
- Vascular leakage and angiogenesis in wound healing: a review.Molecular biology reports · 2025Review
- Targeting diabetic foot ulcer pathophysiology: altered signaling pathways and 3D scaffold as an emerging treatment strategy.3 Biotech · 2025Review
- Molecular Insights into the Superiority of Platelet Lysate over FBS for hASC Expansion and Wound Healing.Cells · 2025Article
- A Comprehensive Literature Review on the Therapeutic Potential of Platelet-Rich Plasma for Diabetic Foot Management: Insights from a Case of a Neglected Deep Plantar Abscess.Healthcare (Basel, Switzerland) · 2025Review
- Platelet lysate-sodium hyaluronate gel promotes diabetic foot wound healing by regulating oxidative stress and autophagy.PloS one · 2025Article
- An Overview of Recent Clinical Trials for Diabetic Foot Ulcer Therapies.Journal of clinical medicine · 2024Review
- Review
- Advanced Platelet Lysate Aerogels: Biomaterials for Regenerative Applications.Journal of functional biomaterials · 2024Article
- Human platelet lysate: a potential therapeutic for intracerebral hemorrhage.Frontiers in neuroscience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Diabetic foot ulcer (DFU) is a major cause of morbidity, non-traumatic lower limb amputation in diabetic patients and a high-cost burden on the healthcare system. New therapeutic products are increasingly tested. Platelet-rich plasma (PRP) and human platelet lysate (hPL) are reported to be useful. This trial was conducted to test whether the healing effect of hPL in chronic DFU was due to plasma or platelet lysates in a prospective double-blind design. Autologous PRP was obtained from citrated blood, lysed, and used as drug 1 (active product). The platelet-poor plasma (PPP) was used as a drug 2 (placebo). Ten patients were enrolled in arm 1 and 9 in arm 2. The drugs were injected perilesionally every 2 weeks for a total of sixinjections. Adverse events were recorded until Week 14. The DFUs were scored per the Texas and Wegner systems. No patient showed any major adverse events. Some reported local pain post-injection. Wound healing was achieved in the hPL group in 9/10 of patients at a mean of 35.1 days. In the PPP group, no patient had healed by Day 84. The difference was statistically significant at P < 0.00001. We conclude that autologous hPL is safe and highly effective in healing chronic DFU and is superior to autologous PPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.